reason report
solid improv profit tripl come anyon
result beat consensu revenu ep driven
strong symdeko uptak lower expect oper
expens total cystic fibrosi cf product revenu
beat consensu grow sequenti
yoy symdeko launch drive increas penetr
vertex medicin elig cf patient popul
reimburs avail momentum continu
next quarter vertex track report data
tripl combin studi earli submit regulatori
applic tripl combin regimen first half next
year beyond cf meaning pipelin updat arent like occur
late still uncertain whether dataset earli clinic
program enough move needl nearli
separ announc yesterday even galapago
sold develop right cf portfolio abbvi
up-front potenti futur mileston royalti
payment may headwind vertex stock near term
due strength galapago data mp
respect competitor market presum longer
theoret potenti acquir vertex
base recent quarter updat model
significantli biggest chang push ramp
symdeko/symkevi tez/iva year base continu
impass reimburs negoti major market outsid us
apart germani result symdeko forecast come
kalydeco
forecast slightli increas orkambi forecast come
due rapid launch symdeko us cannib
orkambi sale domest oper expens also adjust
expect increas sg indic
manag commentari yesterday also account
full statutori taxat pro forma basi chang
result reduct revenu forecast
year reduct earn estim
period long term forecast larg unchang base
chang forecast chang peer compani multipl
reduc price target reiter outperform
average ep revenu multipl
dcf wacc tg
net debt total capit
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu million ep dilut exclud option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate compani stock like everyth biotech vertex stock
sale approach tripl combin catalyst would
encourag investor take advantag disloc build add
posit one cleanest simplest growth stori
product revenu beat consensu fell
short forecast sale symdeko drove top-line beat
symdeko achiev revenu full quarter us
launch symdeko sale consensu estim line
estim orkambi sale quarter fall
short consensu estim howev think
investor unlik view high rate switch orkambi
symdeko neg light sale kalydeco
consensu line estim
gross margin line consensu estim
vertex non-gaap total oper expens
consensu forecast driven lower
sg quarter compani tax rate
non-gaap dilut ep come consensu
estim compani maintain prior full
year cf product revenu guidanc consist
recent consensu maintain full year non-gaap
sg expens guidanc slightli
non cf pipelin slowli attract capit attent vertex
discuss sever pipelin program length confer call
us afterward compani clearli excit gene
edit collabor sickl cell well
pain indic antitrypsin program
schedul enter clinic later year time next year
expect addit data clinic trial
indic time assign valu asset
becom clear program come focu
next coupl year
new price target vertex rate stock outperform thesi
base expect continu captur cystic fibrosi cf patient subpopul
vertex success iter cf modul oral combin medicin expect
vertex cf revenu line grow steadili
probabl success tripl combin valuat account
full expect valu cf portfolio well probabl adjust effect competit entri
beyond consid competitor forecast valuat believ
develop path time market challeng vertex well posit
partner acquir show promis flirt profit past vertex
seem determin maintain recent recov profit appear capabl grow
oper margin end beyond
compani still aspir discov develop drug categori larg diversifi
invest associ expens risk thesi valuat howev
potenti sizabl near-term growth stock offer strong valuat upsid potenti next
continu symdeko uptak market expans us drive revenu
without give much color potenti revenu guidanc cfo ian smith confirm
full-year symdeko revenu contribut us limit adopt outsid us germani
smaller ou market major contributor revenu growth base
orkambi us symdeko revenu previou three quarter estim
approxim current symdeko sale orkambi-switch patient
remain balanc come individu activ treatment either treatment
nave prior orkambi discontinu combin us orkambi/symdeko revenu
compar prior symdeko launch repres compound
quarterli growth unclear critic top-line momentum much addit
penetr vertex achiev elig cf patient vertex medicin
alreadi compani respons question simpli expect
flatten trajectori next quarter imagin time next year ex-
us uptak symdeko may becom meaning top-line growth contributor
yesterday even galapago announc interim result part falcon trial
doubl tripl combin homozyg patient press releas indic
mean increas two week treatment compani
potentiator/corrector doublet combin subsequ two week treatment tripl
combin result addit enhanc cftr activ suggest
galapago moder effect doublet lack viabl triplet combin regimen
least current corrector along data releas also announc
agre acquir world-wide right galapago cf portfolio up-front payment
potenti mileston low teen royalti presum abbvi
believ develop corrector pair galapago doublet viabl tripl
earlier month proteostasi report posit interim data proprietari doublet
small number homozyg cf adult show absolut improv
forc expiratori volum day treatment though patient number small
mid dose cohort benefit day appear compar well orkambi
symdeko phase howev despit potenti strength proteostasi doublet data
yet proven viabl competit strategi address vertex tripl
combin achiev total increas homozyg
patient phase ii proteostasi expect disclos preliminari tripl combin data
later quarter proprietari potentiator/corrector/amplifi triplet differ
vertex potentiator/corrector/corrector combin regimen expect competit
proteostasi either price vertex stock follow initi tripl data
octob vertex crispr announc fda hold ind lift
allow compani initi ex-vivo gene edit trial us subject sickl
cell anemia studi phase i/ii sickl cell beta thalassemia trial
us europ vertex like provid updat patient recruit sometim
first half potenti preliminari data disclosur later year
vertex inhibitor compani advanc non-cf pipelin asset
shown preliminari evid analges effect proof concept post-op pain
osteoarthr studi yesterday vertex describ pain program portfolio molecul
approach on-going year clear compani yet determin
optim medicin take forward larg late-stag studi compani
sever molecul behind current phase ii neuropath pain studi
expect readout earli compani also plan start phase iib
dose rang trial acut pain optimist program
stage given believ rel modest analges effect ill-defin commerci
strategi class medicin recent setback roch program
enhanc skeptic reason includ revenu
perhap promis non-cf compon vertex pipelin antitrypsin
program expect enter clinic end year believ
indic suitabl vertex given rare diseas strong genet basi
diseas singl protein misfold defect clear biomark develop potenti rapid
clinic develop vertex believ experi cf give uniqu advantag
develop small molecul corrector product function protein initi singl
ascend dose multi ascend dose studi healthi patient begin later year
biomark data could disclos late expect learn program
potenti late
slightli lower ex-u revenu bring price outperform
updat revenu expens forecast base recent quarter total
revenu forecast decreas base slower revenu trajectori
outsid us symdeko orkambi less optimist time strength
potenti reimburs agreement orkambi symdeko countri like england
franc vertex fail make progress forecast revenu
symdeko prior estim orkambi ex-u revenu estim
also decreas near term revis total revenu forecast remain
recent consensu estim beyond oper expens estim decreas
base lower sg forecast minim increas estim base
manag team languag potenti trial design durat earlier stage
program base chang pro-forma dilut ep estim increas
decreas later year revis ep estim
consensu recent consensu revis price target
maintain outperform rate
price target vertex base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl higher growth larg cap biopharmaceut compani price sale
multipl mid larg cap high growth biopharmaceut compani discount cash
flow dcf use current averag high growth larg cap biopharma multipl ep
azn appli current ep estim
discount back year compani cost equiti give valu one year
use averag high growth larg cap biotech price-to-revenu multipl sale
nvo appli revenu estim post-tripl
discount back year compani cost equiti give valu one year
lastli dcf valuat given wacc termin cash flow growth rate
give present valu averag three method current price target
risk view outlook valuat vertex includ major chang price
reimburs coverag label competit posit kalydeco orkambi
compani main product today major risk disappoint delay failur
compani develop regulatori file novel tripl combin medicin
cystic fibrosi risk includ continu lack access reimburs vertex
medicin acceler success develop altern modul cftr
altern approach treat cf gene therapi final compani histori
spend much potenti earn expens diversifi acquisit could undermin
futur expect valu compani cf portfolio opportun better-than expect
perform includ realiz signific revenu compani current cf dual
combin market outsid us well acceler clinic develop tripl
sale non-gaap
non-gaap interest expens net
share count period basic
share count period dilut
guidanc
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
cf children year old
cf rare lof mutat cf children
age month
lof mutat cf infant age
time result
cf age
het min cf
het min cf
late stage pipelin program includ
late stage pipelin program exclud
million
product sale po adjust
tripl combin kalydeco second corrector full year sale
total product sale book
product sale po adjust
total product sale book
leerink partner research compani file
million
product sale direct product sale vertex
sale
forma tax excl nol benefit cash
 total revenu
sg total revenu
tax rate note differ pro forma due nol benefit cash
leerink partner research compani file
analysi stock price leerink target
method large-cap healthcar ep multipl lp normal earn
current averag growth larg cap biopharma multipl ep azn
leerink ep
impli price ep use current consensu high growth larg cap multipl
equiti
number period
impli one year target price approach
method discount futur valu normal revenu use mid larg cap biotech compar
averag growth larg cap mid cap biotech price-to-revenu multipl sale
impli vertex enterpris valu sale estimate mm
estimate net
impli vertex equiti valu mm
equiti
number period
impli vertex valu mm
impli one year target price approach
method dcf base current product po adjust outlook cf franchis use wacc
termin cash flow growth rate
present valu late stage market product flow
net debt end
averag method
leerink partner research compani file factset
